Ernexa Therapeutics (ERNAW) Other financing activities (2010 - 2026)
Ernexa Therapeutics' (ERNAW) quarterly Other financing activities came in at $20000.0 in Q1 2026, up 400.0% YoY from $4000.0 in Q1 2025, and down 23.08% on a QoQ basis from $26000.0 in Q3 2025.
Powered by 
Analysis
Ernexa Therapeutics (ERNAW) Other financing activities (2010 - 2026) Analysis & Trends
Ernexa Therapeutics (ERNAW) has 9 years of Other financing activities data on file, last reported at $20000.0 in Q1 2026.
- Quarterly Other financing activities rose 400.0% year-over-year to $20000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46000.0 (up 1050.0% YoY) and the FY2025 annual result came in at $30000.0, changed N/A from the prior year.
- Other financing activities declined to $20000.0 in Q1 2026, from $26000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $26000.0 in Q3 2025 to a low of $4000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ernexa Therapeutics | 67,312.70 | 67,312.70 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Sep 30, 2021 | 10,202.00 |
| Jun 30, 2021 | 10,202.00 |
| Jun 30, 2020 | -1.17 Mn |
| Mar 31, 2020 | 1.17 Mn |
| Jun 30, 2018 | 1.38 Mn |
| Jun 30, 2015 | 1,000.00 |
| Sep 30, 2014 | 22,000.00 |
| Jun 30, 2014 | 17,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Sep 30, 2011 | 2,000.00 |
| Mar 31, 2011 | 34,000.00 |
| Sep 30, 2010 | 5,000.00 |